NEUREN PHARMACEUTICALS LIMITED - Announcements

Market Cap $2.469B Add to my watchlist

Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Announcements

Filter Results

All Price Sensitive Only

NEU	AGM Chairman's Address and CEO Presentation		29/06/20	550.99KB	Share
NEU	Proposed issue of Securities - NEU	PRICE SENSITIVE	29/06/20	33.15KB	Share
NEU	Neuren successfully completes $20m capital raising	PRICE SENSITIVE	29/06/20	131.12KB	Share
NEU	Trading Halt	PRICE SENSITIVE	25/06/20	160.11KB	Share
NEU	Temporary enrolment pause ended in Phase 3 trial in the US	PRICE SENSITIVE	16/06/20	242.24KB	Share
NEU	Change of Director's Interest Notice		02/06/20	34.27KB	Share
NEU	Change of Director's Interest Notice		01/06/20	34.41KB	Share
NEU	Final Director's Interest Notice		29/05/20	26.33KB	Share
NEU	Virtual AGM online guide		28/05/20	1.14MB	Share
NEU	Notice of Annual General Meeting/Proxy Form		28/05/20	247.4KB	Share
NEU	Neuren announces changes to leadership team	PRICE SENSITIVE	27/05/20	132.46KB	Share
NEU	Neuren commences first clinical trial for NNZ-2591	PRICE SENSITIVE	07/05/20	121.9KB	Share
NEU	Appendix 4G		29/04/20	109.71KB	Share
NEU	Annual Report 2019		29/04/20	1.58MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	17/04/20	55.99KB	Share
NEU	Q1 2020 Activity Report	PRICE SENSITIVE	17/04/20	131.81KB	Share
NEU	Corporate presentation, 6 April 2020		06/04/20	1.14MB	Share
NEU	First patent in Israel granted for trofinetide	PRICE SENSITIVE	02/04/20	118.28KB	Share
NEU	Change of Director's Interest Notice		26/03/20	34.3KB	Share
NEU	International institution acquires 14% of Neuren		26/03/20	119.14KB	Share
NEU	Change of Director's Interest Notice		24/03/20	34.31KB	Share
NEU	Temporary pause in new enrolments for LAVENDER trial in US	PRICE SENSITIVE	24/03/20	198.24KB	Share
NEU	Trading Halt	PRICE SENSITIVE	20/03/20	145.49KB	Share
NEU	Neuren to capture substantially greater value after Phase 3	PRICE SENSITIVE	17/03/20	138.58KB	Share
NEU	Additional information		10/03/20	97.07KB	Share
NEU	Compelling results for 2591 dose ranging study in PMS model	PRICE SENSITIVE	06/03/20	184.18KB	Share
NEU	Commentary on potential benefit to Neuren of RPD designation	PRICE SENSITIVE	04/03/20	154.06KB	Share
NEU	Rare Pediatric Disease designation received from FDA	PRICE SENSITIVE	04/03/20	182.01KB	Share
NEU	5 Orphan Drug programs and Rett in Phase 3 funded by partner		26/02/20	814.8KB	Share
NEU	Appendix 4E and 2019 full year accounts	PRICE SENSITIVE	26/02/20	1.15MB	Share
NEU	Update on trofinetide Phase 3 trial in Rett syndrome	PRICE SENSITIVE	19/02/20	101.14KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/20	47.49KB	Share
NEU	2019 year-end update and 2020 outlook	PRICE SENSITIVE	12/12/19	125.65KB	Share
NEU	Patent to 2034 granted in Europe for Neuren's NNZ-2591	PRICE SENSITIVE	03/12/19	122.35KB	Share
NEU	Phase 3 trial of trofinetide in Rett syndrome commences	PRICE SENSITIVE	31/10/19	332.86KB	Share
NEU	Neuren Corporate Presentation, October 2019		18/10/19	1.04MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	17/10/19	47.73KB	Share
NEU	FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins	PRICE SENSITIVE	16/10/19	121.85KB	Share
NEU	Pause in Trading	PRICE SENSITIVE	16/10/19	117.01KB	Share
NEU	FDA grants Orphan Drug Designation for NNZ-2591 in Angelman	PRICE SENSITIVE	11/10/19	120.99KB	Share
NEU	Neuren approaching key milestones in Q4 2019	PRICE SENSITIVE	20/09/19	122.21KB	Share
NEU	Neuren advances pipeline for neurodevelopmental disorders		28/08/19	165.32KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/19	1.37MB	Share
NEU	New patent granted for Neuren's NNZ-2591 in Japan		16/08/19	121.12KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	140.75KB	Share
NEU	Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA		29/07/19	122.4KB	Share
NEU	Neuren receives final payment from Lanstead Capital		16/07/19	117.91KB	Share
NEU	Results of Meeting		28/05/19	57.97KB	Share
NEU	Chairman's Address at 2019 Annual Meeting of Shareholders		28/05/19	141.74KB	Share
NEU	Validation for NNZ-2591 neurodevelopmental disorder pipeline		17/05/19	123.84KB	Share
NEU	NNZ-2591 positive effects in Pitt Hopkins syndrome model	PRICE SENSITIVE	17/05/19	121.68KB	Share
NEU	NNZ-2591 positive effects in Angelman syndrome model	PRICE SENSITIVE	17/05/19	121.73KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	48.3KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		29/04/19	207.53KB	Share
NEU	Appendix 4G		26/04/19	121.86KB	Share
NEU	Annual Report to shareholders		26/04/19	1.35MB	Share
NEU	Update on development plan for NNZ-2591	PRICE SENSITIVE	26/04/19	131.77KB	Share
NEU	Neuren's Rett syndrome Phase 2 trial published in Neurology	PRICE SENSITIVE	28/03/19	239.68KB	Share
NEU	Fundamentals strong as Neuren advances neuroscience pipeline		27/02/19	125.29KB	Share
NEU	Preliminary Final Report and statutory accounts	PRICE SENSITIVE	27/02/19	458.14KB	Share
NEU	NNZ-2591 positive effects in Phelan-McDermid syndrome model	PRICE SENSITIVE	18/02/19	109KB	Share
NEU	Plans for Phase 3 trial in Rett syndrome		04/02/19	72.55KB	Share
NEU	Neuren retains ex-North America, appoints investment bank		01/02/19	104.67KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	47.82KB	Share
NEU	Final Director's Interest Notice		03/01/19	61.4KB	Share
NEU	Ceasing to be a substantial holder		31/12/18	109.75KB	Share
NEU	2018 Year-end Business Update		18/12/18	125.82KB	Share
NEU	Larry Glass to retire as a director and continue as CSO		17/12/18	101.89KB	Share
NEU	Presentation at AusBiotech Invest and Partnering 2018		02/11/18	297.32KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	75.3KB	Share
NEU	Trofinetide ex-North America exclusive negotiation period	PRICE SENSITIVE	26/10/18	100.3KB	Share
NEU	Neuren and ACADIA hold Rett syndrome SAB meeting		17/10/18	102.36KB	Share
NEU	Change of Director's Interest Notice		01/10/18	34.41KB	Share
NEU	FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID		21/09/18	231.09KB	Share
NEU	Investor presentation, 6 September 2018		06/09/18	899.74KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	31/08/18	713.9KB	Share
NEU	Neuren and Lanstead agree to pause settlements for 120 days	PRICE SENSITIVE	29/08/18	102.56KB	Share
NEU	Appointment of auditor		22/08/18	54.1KB	Share
NEU	Neuren receives initial payment of US$10 million from ACADIA	PRICE SENSITIVE	22/08/18	119.21KB	Share
NEU	Change of Director's Interest Notice		16/08/18	34.38KB	Share
NEU	Change of Director's Interest Notice		15/08/18	34.49KB	Share
NEU	Investor update		07/08/18	83.01KB	Share
NEU	Neuren and ACADIA announce agreement for North America	PRICE SENSITIVE	07/08/18	222.12KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	47.69KB	Share
NEU	Initial Director's Interest Notice		09/07/18	62.92KB	Share
NEU	Initial Director's Interest Notice		05/07/18	63.03KB	Share
NEU	Initial Director's Interest Notice		05/07/18	62.82KB	Share
NEU	Neuren announces new appointments to the board of directors		04/07/18	103.77KB	Share
NEU	Results of Meeting		18/06/18	57.13KB	Share
NEU	Chairman's Address at 2018 Annual Shareholders' Meeting		18/06/18	119.92KB	Share
NEU	Change of Director's Interest Notice		30/05/18	41.04KB	Share
NEU	Final share buy-back notice - Appendix 3F		30/05/18	63.11KB	Share
NEU	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	30/05/18	74.27KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		23/05/18	26.99KB	Share
NEU	Appendix 3B		23/05/18	104.19KB	Share
NEU	Neuren announces investment and exclusive negotiation period	PRICE SENSITIVE	21/05/18	99.49KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		14/05/18	194.51KB	Share
NEU	Appendix 4G		08/05/18	124.04KB	Share
NEU	Annual Report to shareholders		08/05/18	3.32MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	62.65KB	Share

NEU AGM Chairman's Address and CEO Presentation
29/06/20		550.99KB	Share
NEU Proposed issue of Securities - NEU
29/06/20	PRICE SENSITIVE	33.15KB	Share
NEU Neuren successfully completes $20m capital raising
29/06/20	PRICE SENSITIVE	131.12KB	Share
NEU Trading Halt
25/06/20	PRICE SENSITIVE	160.11KB	Share
NEU Temporary enrolment pause ended in Phase 3 trial in the US
16/06/20	PRICE SENSITIVE	242.24KB	Share
NEU Change of Director's Interest Notice
02/06/20		34.27KB	Share
NEU Change of Director's Interest Notice
01/06/20		34.41KB	Share
NEU Final Director's Interest Notice
29/05/20		26.33KB	Share
NEU Virtual AGM online guide
28/05/20		1.14MB	Share
NEU Notice of Annual General Meeting/Proxy Form
28/05/20		247.4KB	Share
NEU Neuren announces changes to leadership team
27/05/20	PRICE SENSITIVE	132.46KB	Share
NEU Neuren commences first clinical trial for NNZ-2591
07/05/20	PRICE SENSITIVE	121.9KB	Share
NEU Appendix 4G
29/04/20		109.71KB	Share
NEU Annual Report 2019
29/04/20		1.58MB	Share
NEU Appendix 4C - quarterly
17/04/20	PRICE SENSITIVE	55.99KB	Share
NEU Q1 2020 Activity Report
17/04/20	PRICE SENSITIVE	131.81KB	Share
NEU Corporate presentation, 6 April 2020
06/04/20		1.14MB	Share
NEU First patent in Israel granted for trofinetide
02/04/20	PRICE SENSITIVE	118.28KB	Share
NEU Change of Director's Interest Notice
26/03/20		34.3KB	Share
NEU International institution acquires 14% of Neuren
26/03/20		119.14KB	Share
NEU Change of Director's Interest Notice
24/03/20		34.31KB	Share
NEU Temporary pause in new enrolments for LAVENDER trial in US
24/03/20	PRICE SENSITIVE	198.24KB	Share
NEU Trading Halt
20/03/20	PRICE SENSITIVE	145.49KB	Share
NEU Neuren to capture substantially greater value after Phase 3
17/03/20	PRICE SENSITIVE	138.58KB	Share
NEU Additional information
10/03/20		97.07KB	Share
NEU Compelling results for 2591 dose ranging study in PMS model
06/03/20	PRICE SENSITIVE	184.18KB	Share
NEU Commentary on potential benefit to Neuren of RPD designation
04/03/20	PRICE SENSITIVE	154.06KB	Share
NEU Rare Pediatric Disease designation received from FDA
04/03/20	PRICE SENSITIVE	182.01KB	Share
NEU 5 Orphan Drug programs and Rett in Phase 3 funded by partner
26/02/20		814.8KB	Share
NEU Appendix 4E and 2019 full year accounts
26/02/20	PRICE SENSITIVE	1.15MB	Share
NEU Update on trofinetide Phase 3 trial in Rett syndrome
19/02/20	PRICE SENSITIVE	101.14KB	Share
NEU Appendix 4C - quarterly
28/01/20	PRICE SENSITIVE	47.49KB	Share
NEU 2019 year-end update and 2020 outlook
12/12/19	PRICE SENSITIVE	125.65KB	Share
NEU Patent to 2034 granted in Europe for Neuren's NNZ-2591
03/12/19	PRICE SENSITIVE	122.35KB	Share
NEU Phase 3 trial of trofinetide in Rett syndrome commences
31/10/19	PRICE SENSITIVE	332.86KB	Share
NEU Neuren Corporate Presentation, October 2019
18/10/19		1.04MB	Share
NEU Appendix 4C - quarterly
17/10/19	PRICE SENSITIVE	47.73KB	Share
NEU FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
16/10/19	PRICE SENSITIVE	121.85KB	Share
NEU Pause in Trading
16/10/19	PRICE SENSITIVE	117.01KB	Share
NEU FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
11/10/19	PRICE SENSITIVE	120.99KB	Share
NEU Neuren approaching key milestones in Q4 2019
20/09/19	PRICE SENSITIVE	122.21KB	Share
NEU Neuren advances pipeline for neurodevelopmental disorders
28/08/19		165.32KB	Share
NEU Half Yearly Report and Accounts
28/08/19	PRICE SENSITIVE	1.37MB	Share
NEU New patent granted for Neuren's NNZ-2591 in Japan
16/08/19		121.12KB	Share
NEU Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	140.75KB	Share
NEU Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
29/07/19		122.4KB	Share
NEU Neuren receives final payment from Lanstead Capital
16/07/19		117.91KB	Share
NEU Results of Meeting
28/05/19		57.97KB	Share
NEU Chairman's Address at 2019 Annual Meeting of Shareholders
28/05/19		141.74KB	Share
NEU Validation for NNZ-2591 neurodevelopmental disorder pipeline
17/05/19		123.84KB	Share
NEU NNZ-2591 positive effects in Pitt Hopkins syndrome model
17/05/19	PRICE SENSITIVE	121.68KB	Share
NEU NNZ-2591 positive effects in Angelman syndrome model
17/05/19	PRICE SENSITIVE	121.73KB	Share
NEU Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	48.3KB	Share
NEU Notice of Annual General Meeting/Proxy Form
29/04/19		207.53KB	Share
NEU Appendix 4G
26/04/19		121.86KB	Share
NEU Annual Report to shareholders
26/04/19		1.35MB	Share
NEU Update on development plan for NNZ-2591
26/04/19	PRICE SENSITIVE	131.77KB	Share
NEU Neuren's Rett syndrome Phase 2 trial published in Neurology
28/03/19	PRICE SENSITIVE	239.68KB	Share
NEU Fundamentals strong as Neuren advances neuroscience pipeline
27/02/19		125.29KB	Share
NEU Preliminary Final Report and statutory accounts
27/02/19	PRICE SENSITIVE	458.14KB	Share
NEU NNZ-2591 positive effects in Phelan-McDermid syndrome model
18/02/19	PRICE SENSITIVE	109KB	Share
NEU Plans for Phase 3 trial in Rett syndrome
04/02/19		72.55KB	Share
NEU Neuren retains ex-North America, appoints investment bank
01/02/19		104.67KB	Share
NEU Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	47.82KB	Share
NEU Final Director's Interest Notice
03/01/19		61.4KB	Share
NEU Ceasing to be a substantial holder
31/12/18		109.75KB	Share
NEU 2018 Year-end Business Update
18/12/18		125.82KB	Share
NEU Larry Glass to retire as a director and continue as CSO
17/12/18		101.89KB	Share
NEU Presentation at AusBiotech Invest and Partnering 2018
02/11/18		297.32KB	Share
NEU Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	75.3KB	Share
NEU Trofinetide ex-North America exclusive negotiation period
26/10/18	PRICE SENSITIVE	100.3KB	Share
NEU Neuren and ACADIA hold Rett syndrome SAB meeting
17/10/18		102.36KB	Share
NEU Change of Director's Interest Notice
01/10/18		34.41KB	Share
NEU FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
21/09/18		231.09KB	Share
NEU Investor presentation, 6 September 2018
06/09/18		899.74KB	Share
NEU Half Yearly Report and Accounts
31/08/18	PRICE SENSITIVE	713.9KB	Share
NEU Neuren and Lanstead agree to pause settlements for 120 days
29/08/18	PRICE SENSITIVE	102.56KB	Share
NEU Appointment of auditor
22/08/18		54.1KB	Share
NEU Neuren receives initial payment of US$10 million from ACADIA
22/08/18	PRICE SENSITIVE	119.21KB	Share
NEU Change of Director's Interest Notice
16/08/18		34.38KB	Share
NEU Change of Director's Interest Notice
15/08/18		34.49KB	Share
NEU Investor update
07/08/18		83.01KB	Share
NEU Neuren and ACADIA announce agreement for North America
07/08/18	PRICE SENSITIVE	222.12KB	Share
NEU Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	47.69KB	Share
NEU Initial Director's Interest Notice
09/07/18		62.92KB	Share
NEU Initial Director's Interest Notice
05/07/18		63.03KB	Share
NEU Initial Director's Interest Notice
05/07/18		62.82KB	Share
NEU Neuren announces new appointments to the board of directors
04/07/18		103.77KB	Share
NEU Results of Meeting
18/06/18		57.13KB	Share
NEU Chairman's Address at 2018 Annual Shareholders' Meeting
18/06/18		119.92KB	Share
NEU Change of Director's Interest Notice
30/05/18		41.04KB	Share
NEU Final share buy-back notice - Appendix 3F
30/05/18		63.11KB	Share
NEU Announcement of buy-back - Appendix 3C
30/05/18	PRICE SENSITIVE	74.27KB	Share
NEU Notice under section 708A(5)(e) of the Corporations Act
23/05/18		26.99KB	Share
NEU Appendix 3B
23/05/18		104.19KB	Share
NEU Neuren announces investment and exclusive negotiation period
21/05/18	PRICE SENSITIVE	99.49KB	Share
NEU Notice of Annual General Meeting/Proxy Form
14/05/18		194.51KB	Share
NEU Appendix 4G
08/05/18		124.04KB	Share
NEU Annual Report to shareholders
08/05/18		3.32MB	Share
NEU Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	62.65KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $19.34		Change 0.320(1.68%)		Mkt cap ! $2.469B

Open	High	Low	Value	Volume
$19.20	$19.41	$18.55	$13.89M	728.4K

Buyers (Bids)

No.	Vol.	Price($)
1	624	$19.34

Sellers (Offers)

Price($)	Vol.	No.
$19.35	6719	2

View Market Depth

No.	Vol.	Price($)
2	403	20.300
1	85	19.590
1	26	19.440
1	50	19.410
1	500	19.400

Price($)	Vol.	No.
18.380	27	1
18.430	234	1
18.760	297	1
18.780	24	1
18.820	32	1

Last trade - 16.10pm 05/06/2024 (20 minute delay)


Last $19.40		Change 0.320 ( 1.70 %)
Open	High	Low	Volume
$19.12	$19.40	$18.55	139309
Last updated 15.59pm 05/06/2024 ?

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories